Kelmendi Benjamin, Adams Thomas G, Southwick Steven, Abdallah Chadi G, Krystal John H
Clinical Neuroscience Division, Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT.
Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
Clin Psychol (New York). 2017 Sep;24(3):281-297. doi: 10.1111/cpsp.12202. Epub 2017 Jul 18.
Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. While these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD that suggest novel approaches to pharmacotherapy.
三十年来对创伤后应激障碍生物学的研究，为与该疾病药物治疗潜在机制相关的假说奠定了基础。美国食品药品监督管理局仅批准了两种药物，舍曲林和帕罗西汀，用于治疗创伤后应激障碍。虽然这些药物有一定疗效，但仍须探索其他治疗机制，以满足有效治疗的未竟需求。本文简要总结了我们对创伤后应激障碍神经生物学的理解进展，这些进展提示了药物治疗的新方法。
